Last reviewed · How we verify
NCT05134792
Effect of Pre-emptive Intravenous Immunoglobulin (IVIG) on the Incidence of Septic Episodes in Pediatric Burn Patients
Phase 2, PHASE3 trial testing intravenous immunoglobulin in Burn Shock in 30 participants. Completed in 16 July 2022.
16 July 2022
Quick facts
| Lead sponsor | Cairo University |
|---|---|
| Phase | Phase 2, PHASE3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 30 |
| Start date | 10 October 2021 |
| Primary completion | 16 July 2022 |
| Estimated completion | 16 July 2022 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- intravenous immunoglobulin — full drug profile →
Conditions studied
- Burn Shock — all drugs for Burn Shock →
Sponsor
Cairo University
Who can join
Adults 1 to 5, any sex, with Burn Shock. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Effect of pre-emptive intravenous immunoglobulin administration on the incidence of septic episodes in pediatric burn patients: A randomized controlled study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05134792
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of intravenous immunoglobulin
Trials testing the same drug.
- NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
- NCT05634824 — IVIg Plus Low Dose rhTPO for ITP in Pregnancy · Phase 2 · unknown
- NCT05520892 — Two Regimens of IVIG in the Treatment of Newly Diagnosed ITP in Children · Phase 4 · recruiting
- NCT05604859 — Evaluate the Efficacy and Safety of Various Treatment Schemes for Severe Fever With Thrombocytopenia Syndrome(SFTS) · Phase 4 · unknown
- NCT03130517 — Efficacy of Intravenous Immunoglobulin in Management of Rh and ABO Incompatibility Disease · EARLY_PHASE1 · unknown
Other Cairo University trials
Trials by the same sponsor.
- NCT04155528 — Effect of Music Therapy on Postoperative Health Outcomes · NA · not yet recruiting
- NCT07363239 — CBCT-Based Safety Distance for Implant Placement Near the Inferior Alveolar Canal · not yet recruiting
- NCT07374575 — Egyptian Dental Professionals' Perspectives on the Oral Microbiome and Exosomes · not yet recruiting
- NCT07381153 — In-Vitro Cytotoxicity Assessment of INOX (Nanoksa G Plus) Polymer Discs · not yet recruiting
- NCT07375394 — 3D-Printed Extraoral Camera for Standardized Dental Photography · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05134792 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cairo University
- Last refreshed: 15 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05134792.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing